Tumor News and Research

RSS

CNS experts create new research-based guidelines for evaluation and treatment of NFPAs

Nonfunctioning pituitary adenomas (NFPAs) are common benign tumors that may be present for years before causing any symptoms.

26 Sep 2016

Addition of chemotherapy to post-surgical radiation treatment improves survival in medulloblastoma patients

In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival.

26 Sep 2016

Specific high-fat diets linked to increased tumor formation in mouse model of intestinal cancer

A high-fat-diet-induced immune reaction causes inflammation leading to intestinal cancer in a mouse model - even among animals that are not obese -- according to a new study from the Perelman School of Medicine at the University of Pennsylvania, Case Western Reserve University, the Pacific Northwest Research Institute, and others.

26 Sep 2016

Study reveals radiosurgery as viable treatment option for patients with resected brain metastases

For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in statistically comparable survival rates, reduced cognitive decline and better quality of life (QOL), compared to whole brain radiotherapy (WBRT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.

26 Sep 2016

University of Bonn researchers develop new method to combat complex brain tumors

Glioblastomas are incurable malignant brain tumors. Usually the patients affected survive for only a few months.

26 Sep 2016

$Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients$

Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.

26 Sep 2016

SRS reduces likelihood of local recurrence of brain metastases in cancer patients

Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence but shows no positive difference in terms of overall survival (OS) or distant brain metastases (DBMs) rates, when compared to observation alone following surgical resection of brain metastases, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.

26 Sep 2016

Researchers identify, validate three distinct molecular subtypes of prostate cancer

In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.

26 Sep 2016

Increased use of SBRT linked to improved survival outcomes of NSCLC patients

A new analysis of records in the Veteran's Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) in recent years, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.

26 Sep 2016

Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease.

26 Sep 2016

Salk scientist Clodagh O'Shea named recipient of grant from Faculty Scholars Program

Clodagh O'Shea, an associate professor in the Salk Institute's Molecular and Cell Biology Laboratory, is among the first recipients of a grant from the Faculty Scholars Program, a new partnership of Howard Hughes Medical Institute, the Bill & Melinda Gates Foundation and the Simons Foundation for early career researchers whose work shows the potential for groundbreaking contributions in their fields.

24 Sep 2016

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis announced today that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.

24 Sep 2016

Multifunctional nanocapsules could enhance drug delivery to specific disease sites

A nanoparticle-based drug delivery system that can sense and respond to different conditions in the body, as well as to an externally applied magnetic field, could enhance doctors’ ability to target drugs to specific sites of disease.

24 Sep 2016

FDA approves new biosimilar for multiple inflammatory diseases

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.

23 Sep 2016

New global map shines light on genetic roots of diseases

A global genetic interaction map is revolutionizing how genes are being studied. A new study, involving University of Minnesota researchers, is no longer looking at genes as loners, but instead as a social network of the body, interacting in groups. The new approach may ultimately change our understanding of the genetic roots of diseases.

23 Sep 2016

Yale researchers compare efficacy of four PD-L1 assay tests

In a recent study, a Yale Cancer Center team compared the performance of the four available PD-L1 assay tests.

23 Sep 2016

Ludwig researchers shed more light on key requirement for function of regulatory T cells

A Ludwig Cancer Research study published online September 5th in Nature Immunology illuminates a key requirement for the function of regulatory T cells—immune cells that play a critical role in many biological processes, from suppressing inflammation and deadly autoimmunity to helping tumors evade immune attack.

23 Sep 2016

Magnetic bacteria can be promising vehicle for efficiently delivering tumor-fighting drugs

Researchers funded in part by the National Institute of Biomedical Imaging and Bioengineering have recently shown that magnetic bacteria are a promising vehicle for more efficiently delivering tumor-fighting drugs. They reported their results in the August 2016 issue of Nature Nanotechnology.

23 Sep 2016

One single genomic fingerprinting could potentially miss smaller, more aggressive prostate tumors

While the majority of prostate cancers are slow growing and not fatal, some are aggressive and lethal.

22 Sep 2016

Novel immunotherapy shows promise against AML in clinical trial

A new type of immunotherapy shows promise against cases of acute myeloid leukemia (AML) that recur after treatment or that never respond to therapy in the first place.

21 Sep 2016

Tumor News and Research

CNS experts create new research-based guidelines for evaluation and treatment of NFPAs

Addition of chemotherapy to post-surgical radiation treatment improves survival in medulloblastoma patients

Specific high-fat diets linked to increased tumor formation in mouse model of intestinal cancer

Study reveals radiosurgery as viable treatment option for patients with resected brain metastases

University of Bonn researchers develop new method to combat complex brain tumors

Hypofractionated RT can reduce treatment time by half in stage II and III NSCLC patients

SRS reduces likelihood of local recurrence of brain metastases in cancer patients

Researchers identify, validate three distinct molecular subtypes of prostate cancer

Increased use of SBRT linked to improved survival outcomes of NSCLC patients

Approval of PD-1 inhibitor scratches surface of potential immunotherapies in recurrent HNSCC

Salk scientist Clodagh O'Shea named recipient of grant from Faculty Scholars Program

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Multifunctional nanocapsules could enhance drug delivery to specific disease sites

FDA approves new biosimilar for multiple inflammatory diseases

New global map shines light on genetic roots of diseases

Yale researchers compare efficacy of four PD-L1 assay tests

Ludwig researchers shed more light on key requirement for function of regulatory T cells

Magnetic bacteria can be promising vehicle for efficiently delivering tumor-fighting drugs

One single genomic fingerprinting could potentially miss smaller, more aggressive prostate tumors

Novel immunotherapy shows promise against AML in clinical trial

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News